^
Association details:
| Biomarker: | NTRK3 fusion |
|---|---|
| Cancer: | Neurofibrosarcoma |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
ROZLYTREK is a kinase inhibitor indicated for the treatment of...Adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation.
Source:
Title:
An updated analysis of the clinical efficacy and safety of entrectinib in NTRK fusion-positive sarcoma
Published date:
11/18/2020
Excerpt:
After a median follow-up of 17.74 months (95% CI 9.95–22.57), the confirmed ORR was 56.3% (95% CI 29.9–80.3...The majority of patients with sarcoma experienced a reduction in tumour lesion size, including those with CNS metastases at baseline...Entrectinib continued to achieve clinically meaningful, durable responses, demonstrating overall efficacy in patients with NTRK fusion-positive sarcoma.
